# Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

> **NCT04624711** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 40 (estimated)

## Conditions studied

- HER2-negative Breast Cancer

## Interventions

- **DRUG:** Eribulin Mesylate
- **DRUG:** Anlotinib hydrochloride

## Key facts

- **NCT ID:** NCT04624711
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2022-06
- **Final completion:** 2022-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624711, "Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04624711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*